The Board consists of not more than five members who serve on a part-time basis, appointed by the Governor-in-Council, including a Chairperson and a Vice-chairperson. The Chairperson is designated under the Patent Act as the Chief Executive Officer of the PMPRB with the authority and responsibility to supervise and direct its work. By operation of law, the Vice-chairperson exercises all the powers and functions of the Chairperson should the Chairperson be absent or incapacitated, or if the office of the Chairperson is vacant.
Find out more about the roles and responsibilities of Board Members.
Mitchell Levine, BSc (McGill), MSc (McMaster), MD (Calgary), FRCPC, FISPE
Dr. Mitchell Levine was appointed Chairperson of the Board on February 13, 2018.
Dr. Levine is a professor in the
department of Health Research Methods, Evidence and Impact and the department
of Medicine in the Faculty of Health Sciences at McMaster University in
Hamilton, Ontario. He is also director of the Centre for Evaluation of
Medicines at St. Joseph's Healthcare in Hamilton.
Dr. Levine received his medical degree from the University of Calgary in 1979, which was followed by postgraduate training in Internal Medicine (FRCPC) and Clinical Pharmacology at the University of Toronto (1981–1987). He received an MSc degree in Clinical Epidemiology from McMaster University in 1988.
Until his appointment to the Board, Dr. Levine was a member of the Patented Medicine Prices Review Board's Human Drug Advisory Panel. He acts, on an ad hoc basis, as a clinical pharmacology consultant to the Ontario Ministry of Health and Long-Term Care. In addition, he is the Editor-in-Chief of the Journal of Population Therapeutics and Clinical Pharmacology and Associate Editor of the ACP Journal Club: Evidence-Based Medicine.
Dr. Levine previously served as a Member and Vice-Chairperson of the Board since 2011.
Carolyn Kobernick is a lawyer and former career public servant. Prior to her retirement in 2013, Ms. Kobernick had been Assistant Deputy Minister of Public Law for the Department of Justice since 2006. As principal counsel to the Minister of Justice and Attorney General of Canada, Ms. Kobernick was instrumental in the development and delivery of policy for the Public Law sector. In addition to identifying key strategic, legal and operational matters, she tackled cross-cutting national issues as the liaison between the Department of Justice and other government organizations.
Ms. Kobernick joined the Department of Justice in 1980 where she practiced litigation and tax law at the Toronto Regional office. In 1991 she was appointed Senior General Counsel, Deputy Head, Business and Regulatory Law Portfolio, after working for over a decade in the legal services unit of the Correctional Service of Canada. In her role as Senior General Counsel, Ms. Kobernick was involved in complex policy and operational issues affecting the Government of Canada, including the Alaska Pipeline and Mackenzie Valley Pipeline files and the Sponsorship file.
During her career with the public service, Ms. Kobernick actively participated in many high-profile initiatives. She was Chair of the National Legal Advisory Committee and Departmental Champion for Aboriginal People and Gender Equity. She also served as the Senior Department of Justice official at the Domestic Affairs Cabinet Committee, and was appointed Senior Legal Advisor to the Government of Canada for the 2004 Gomery Inquiry.
Ms. Kobernick holds a B.C.L. and L.L.B. from McGill University and is a member of the bar of Ontario. In 2012 she obtained a Certificate in Adjudication for Administrative Agencies Boards and Tribunals from the Osgoode Hall Law School and The Society of Adjudicators and Regulators.
Regulatory Affairs and Outreach
The Regulatory Affairs and Outreach Branch reviews the prices of patented drug products sold in Canada to ensure that they are not excessive; encourages patentees to comply voluntarily with the Board’s Guidelines; implements related compliance policies; and investigates complaints into the prices of patented medicines. This branch also informs and educates patentees on the Board’s Guidelines and filing requirements.
Policy and Economic Analysis
The Policy and Economic Analysis Branch develops policy and strategic advice; makes recommendations on possible amendments to the Board’s Guidelines; conducts research and analysis on the prices of drugs, pharmaceutical market developments and R&D trends; and publishes studies aimed at providing F/P/T governments and other interested stakeholders with centralized, credible information in support of evidence based policy.
The Corporate Services Branch provides advice and services in relation to human resources management; facilities; procurement; health, safety and security; information technology; and information management. It is also responsible for financial planning and reporting, accounting operations, audit and evaluation, and liaising with federal central agencies on these topics.
Board Secretariat, Communications and Strategic Planning
The Board Secretariat, Communications and Strategic Planning Branch develops and manages the PMPRB’s communications, media relations, and public enquiries; manages the Board’s meeting and hearing processes, including the official record of proceedings; and coordinates activities pursuant to the Access to Information Act and the Privacy Act. It is also responsible for strategic planning and reporting.
The General Counsel advises the PMPRB on legal matters and leads the legal team representing Board Staff in proceedings before the Board.